Here is information about stomach cancer, risk factors, symptoms, screening, early detection, diagnosis, staging, choosing a treatment facility, treatments, chemotherapy, surgery, radiation, molecular testing, genetics, clinical trials, and what’s new in the diagnosis and treatment of stomach cancer. If you have any questions, contact our office at (855) 475-1200 or email us at Programs@DebbiesDream.org. All services are free, and we would be happy to help!
Stomach Cancer Overview
Stomach cancer is the fifth most common type of cancer and the fourth leading cause of cancer death globally. In 2026, approximately 30,300 Americans will be diagnosed with stomach cancer, and nearly 11,000 will lose their lives to the disease. The overall five‑year relative survival rate is about 36%, dropping to just 7% for stage IV, highlighting the urgent need for increased awareness and research. Stomach cancer also disproportionately affects minority populations, with Native American, Black, Asian, Pacific Islander, and Hispanic communities experiencing significantly higher mortality rates compared to White populations. While the incidence of stomach cancer has been dropping steadily in the United States since World War II, it remains a major global health problem. Japan, China, South Korea, Taiwan, Costa Rica, Peru, Brazil, Chile, and several countries of the former Soviet Union continue to have very high incidence rates, influenced in part by diets rich in heavily smoked, salted, and pickled foods.
Stomach (Gastric) Cancer Survival Rates
Survival rates for stomach cancer are based on the stage at diagnosis and show the percentage of people who are alive five years after their cancer is found. These numbers are meant to be general guidelines, not predictions for any one person. They reflect relative survival, which compares people with stomach cancer to people of the same age in the general population.
Every patient is different, and many factors affect outcomes, including age, overall health, and how the cancer responds to treatment. Your doctor can help you understand how these statistics relate to your situation, though they may not be able to predict life expectancy. The survival rates below come from the National Cancer Institute’s SEER Program.
| Extent of Disease | Cases by stage (%) | 5-year Relative Survival (%) |
| Localized (confined to primary site) | 31 | 76.5 |
| Regional (spread to regional lymph nodes) | 24 | 37.2 |
| Distant (Cancer has metastasized) | 36 | 7.5 |
| Unknown (unstaged) | 10 | 31.9 |
For more information see the National Cancer Institute website at
http://seer.cancer.gov/statfacts/html/stomach.html
Stomach Cancer Guidelines for Patients
Debbies’s Dream Foundation: Curing Stomach Cancer has partnered with the National Comprehensive Cancer Network to provide the most up-to-date guidelines for patients. NCCN Guidelines for Patients®, patient-friendly translations of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), are meant to help patients with cancer talk with their physicians about the best treatment options for their disease.
2026 NCCN Stomach Cancer Guidelines
Additional Downloads
Help us educate & inform.
Your donations make the difference.
Ask the Expert: The Role of Biomarkers in Stomach Cancer
Debbie’s Dream Foundation: Curing Stomach Cancer is proud to present an insightful interview with Dr. Samuel Klempner, GI Medical Oncologist of Massachusetts General Hospital Cancer Center and Harvard Medical School, titled “Ask the Expert: The Role of Biomarkers in Stomach Cancer.”
In this interview, Dr. Klempner discusses the importance of biomarker testing in the diagnosis and treatment of stomach cancer. Understanding the role of biomarkers can help guide personalized treatment plans and improve patient outcomes.
Watch the full interview to learn more about how biomarkers can impact your care.

Biomarkers Educational Videos
Co-branded with CancerCare and featuring other industry partners, these videos provide invaluable insights, resources, and support to help you navigate understanding your biomarkers with confidence and understanding.